Company Encyclopedia
View More
name
Cyclerion Therapeutics
CYCN.US
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
1.946 T
CYCN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking48/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-24.80%E
    • Profit Margin-77.02%E
    • Gross Margin60.23%A
  • Growth ScoreA
    • Revenue YoY1371.65%A
    • Net Profit YoY58.36%B
    • Total Assets YoY17.05%A
    • Net Assets YoY16.35%A
  • Cash ScoreB
    • Cash Flow Margin-129.83%D
    • OCF YoY1371.65%A
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreA
    • Gearing Ratio8.42%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pre-market hot trades in US stocks: Lithium Americas up 9.48% pre-market; Cyclerion Therapeutics down 8.00% pre-market

    Lithium Americas pre-market up 9.48%; Cyclerion Therapeutics pre-market down 8.00%; PepGen pre-market up 91.35%; WORK Medical Tech pre-market up 59.82%; OFA pre-market up 40.60%

    Tracking Unusual Activity·
    US
    LAC
    +3.62%
    US
    CYCN
    +11.11%
    Tracking Unusual Activity·
    US
    LAC
    +3.62%
    US
    CYCN
    +11.11%

    BUZZ-Cyclerion Therapeutics jumps on MIT deal to develop depression drug

    Shares of drug developer Cyclerion Therapeuticsrise 43% to $4.33 premarketCo said late on Tuesday it is relaunching as a neuropsychiatric-focused firm after signing a licensing deal with the Massachusetts Institute of TechnologyIts lead program targets treatment-resistant depression using anesthetic-based techA mid-stage trial is expected to begin in 2026 with data in 2027, co saidAs of last close, stock down 6.2% YTD

    Reuters·
    US
    CYCN
    +11.11%
    Reuters·
    US
    CYCN
    +11.11%

    Biotech Stocks Surge After Hours On Trial Updates And Strategic Moves

    After-hours trading on Tuesday saw significant gains in biotech stocks, driven by clinical updates and strategic announcements. Cyclerion Therapeutics surged 48.01% after announcing a relaunch focused on neuropsychiatric therapies. Clearside Biomedical rose 6.82% following presentations at the EURETINA Congress. Reviva Pharmaceuticals gained 11.50% ahead of an investor conference. Acumen Pharmaceuticals and PepGen also saw increases, with Acumen confirming data timelines for its trials. Corcept Therapeutics announced upcoming presentations and PDUFA dates, contributing to its 4.54% rise.

    rttnews·
    US
    CYCN
    +11.11%
    US
    ABOS
    +2.59%
    US
    RVPH
    -0.57%
    rttnews·
    US
    CYCN
    +11.11%
    US
    ABOS
    +2.59%
    US
    RVPH
    -0.57%

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    In Tuesday's after-market session, several health care stocks saw significant movements. Cyclerion Therapeutics (CYCN) surged 47.4% to $4.45, with a market value of $9.7 million. Applied Therapeutics (APLT) rose 11.21% to $0.5, valued at $68.5 million. Rallybio (RLYB) increased by 6.29% to $0.62, with a market cap of $25.4 million. SAB Biotherapeutics (SABS) gained 6.19% to $2.4, valued at $23.0 million. AN2 Therapeutics (ANTX) rose 5.79% to $1.35, with a market value of $36.6 million, and Adaptimmune Therapeutics (ADAP) increased by 5.26% to $0.16, valued at $44.3 million.

    Benzinga·
    US
    RLYB
    +1.00%
    US
    SABS
    +2.70%
    US
    APLT
    +8.85%
    Benzinga·
    US
    RLYB
    +1.00%
    US
    SABS
    +2.70%
    US
    APLT
    +8.85%

    Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

    CAMBRIDGE, Mass., Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Cyclerion Therapeutics, Inc. today announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology ( "MIT" ) , securing the intellectual property that will serve as the cornerstone of its strategic ...

    Benzinga·
    US
    CYCN
    +11.11%
    Benzinga·
    US
    CYCN
    +11.11%
    © 2025 Longbridge｜Disclaimer